📊 AMIX Key Takeaways
Is Autonomix Medical, Inc. (AMIX) a Good Investment?
Autonomix Medical is a pre-revenue medical device company with zero revenue and significant ongoing cash burn of $9.4M annually, indicating the company has not yet achieved commercial traction. With only $9.9M in cash and negative operating cash flow, the company has approximately 12 months of runway before potential capital depletion, absent additional funding or a major inflection in commercialization.
Autonomix Medical remains a pre-revenue medical device company with no demonstrated commercial traction and significant ongoing operating losses. While the balance sheet is currently liquid and leverage is modest, cash burn is high relative to its cash balance, making future capital raises or dilution a meaningful risk unless revenue generation improves materially.
Why Buy Autonomix Medical, Inc. Stock? AMIX Key Strengths
- Strong current ratio of 6.18x indicates short-term liquidity to meet near-term obligations
- Conservative balance sheet with low debt-to-equity ratio of 0.17x minimizes financial leverage risk
- Minimal capital expenditure of $7K suggests asset-light business model focused on development rather than infrastructure
- Strong near-term liquidity with cash representing most of total assets
- Low debt burden relative to equity
- Minimal capital expenditure needs keep infrastructure intensity low at this stage
AMIX Stock Risks: Autonomix Medical, Inc. Investment Risks
- Zero revenue despite being a publicly traded company indicates inability to commercialize product or gain market adoption
- Negative operating cash flow of -$9.4M combined with $9.9M cash balance creates imminent funding requirement within 12 months
- Massive negative returns on equity (-164.1%) and assets (-137.6%) demonstrate value destruction and failed product-market fit
- No insider activity in past 90 days suggests lack of management confidence and potential disengagement
- Complete absence of gross profit prevents assessment of unit economics and operational viability
- No revenue base or gross profit, leaving the business model unproven
- Heavy operating and free cash flow losses imply limited cash runway
- Very weak returns on assets and equity indicate poor current capital efficiency
Key Metrics to Watch
- Revenue recognition and commercial traction milestones
- Cash burn rate and remaining runway before funding requirement
- Operating cash flow improvement trajectory and path to breakeven
- Quarterly revenue/commercialization progress
- Operating cash burn relative to cash and equivalents
Autonomix Medical, Inc. (AMIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.18x current ratio provides a solid financial cushion.
AMIX Profit Margin, ROE & Profitability Analysis
AMIX vs Healthcare Sector: How Autonomix Medical, Inc. Compares
How Autonomix Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Autonomix Medical, Inc. Stock Overvalued? AMIX Valuation Analysis 2026
Based on fundamental analysis, Autonomix Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Autonomix Medical, Inc. Balance Sheet: AMIX Debt, Cash & Liquidity
AMIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Autonomix Medical, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.82 indicates the company is currently unprofitable.
AMIX Revenue Growth, EPS Growth & YoY Performance
AMIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$2.7M | $-0.36 |
| Q2 2026 | N/A | -$2.7M | $-1.38 |
| Q1 2026 | N/A | -$2.7M | $-1.07 |
| Q3 2025 | N/A | -$865.0K | $-1.46 |
| Q2 2024 | N/A | -$865.0K | $-2.47 |
| Q1 2024 | N/A | -$865.0K | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Autonomix Medical, Inc. Dividends, Buybacks & Capital Allocation
AMIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Autonomix Medical, Inc. (CIK: 0001617867)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMIX
What is the AI rating for AMIX?
Autonomix Medical, Inc. (AMIX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMIX's key strengths?
Claude: Strong current ratio of 6.18x indicates short-term liquidity to meet near-term obligations. Conservative balance sheet with low debt-to-equity ratio of 0.17x minimizes financial leverage risk. ChatGPT: Strong near-term liquidity with cash representing most of total assets. Low debt burden relative to equity.
What are the risks of investing in AMIX?
Claude: Zero revenue despite being a publicly traded company indicates inability to commercialize product or gain market adoption. Negative operating cash flow of -$9.4M combined with $9.9M cash balance creates imminent funding requirement within 12 months. ChatGPT: No revenue base or gross profit, leaving the business model unproven. Heavy operating and free cash flow losses imply limited cash runway.
What is AMIX's revenue and growth?
Autonomix Medical, Inc. reported revenue of $0.0.
Does AMIX pay dividends?
Autonomix Medical, Inc. does not currently pay dividends.
Where can I find AMIX SEC filings?
Official SEC filings for Autonomix Medical, Inc. (CIK: 0001617867) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMIX's EPS?
Autonomix Medical, Inc. has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMIX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Autonomix Medical, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AMIX stock overvalued or undervalued?
Valuation metrics for AMIX: ROE of -164.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AMIX stock in 2026?
Our dual AI analysis gives Autonomix Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMIX's free cash flow?
Autonomix Medical, Inc.'s operating cash flow is $-9.4M, with capital expenditures of $7.0K.
How does AMIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -164.1% (avg: 15%), current ratio 6.18 (avg: 2).